ClinicalTrials.gg
RecruitingNCT07041099Updated Aug 11, 2026

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

A Phase 1 interventional study of CLN-978 in Sjögren, Sjogren Disease and Sjogren's Syndrome, sponsored by Cullinan Therapeutics Inc.. Recruiting at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Cullinan Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Planned enrollment
46th of 76
36 · median 57
Started
2025
with 5 others
Phase 1
15 of 111
5 open now
Primary completion
2028-03
later than 11 of 27 live
Registered
102nd of 111
by date

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 46th largest by planned enrollment of the 76 interventional ones that give a count, is one of 6 that started in 2025, is one of 15 in phase 1, reaches primary completion later than 11 of the 27 other live ones, and was the 102nd registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

03

Conditions studied

  • Sjögren
  • Sjogren Disease
  • Sjogren's Syndrome

Browse trials for

Keywords

  • CLN-978
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SjD at least 24 weeks prior to Screening Visit and meet the 2016 EULAR / ACR Classification Criteria for SjD at Screening.
  • Have active moderate to severe disease (i.e., ESSDAI ≥5) at Screening.
  • Laboratory parameters including the following:

    • Absolute lymphocyte count (ALC) ≥0.5 × 10\^9/L
    • Peripheral CD19+ B cell count ≥25 cells/µL
    • (ANC) ≥1.0 × 10\^9/L
    • (Hgb) ≥8 g/dL
    • count ≥75 × 10\^9/L
    • Total ≤1.5 × , except patients with confirmed Gilbert's Syndrome
    • (AST) and Alanine aminotransferase (ALT) ≤2.0 × ULN
    • Estimated (eGFR) based on the CKD-EPI formula ≥30 mL/min/1.73 m2

Exclusion criteria

Exclusion

  • Concomitant rheumatological disease
  • Considered at high risk for thrombosis
  • Rapidly progressive glomerulonephritis and/or urine protein/creatinine >3 mg/mg (339 mg/mmol).
  • Active, severe central nervous system manifestations of SjD.
  • History of stroke, seizure, dementia, Parkinson's disease, coordination movement disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic disorder that the Investigator feels would put the patient at undue risk or confound study results.
  • Evidence of virus (HBV), virus (HCV), (HIV), Epstein-Barr virus (EBV), or cytomegalovirus (CMV) infection.
  • Primary immunodeficiency or history of recurrent infections.
  • History of splenectomy.
  • Live or attenuated vaccine within 28 days prior to the Screening Visit or during the Screening Period.
  • Active, bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, within 14 days prior to Day 1.
  • Active or latent tuberculosis (TB)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Part A Dose Escalation

    Patients with Sjogren's Disease treated with CLN-978 in dose escalation cohorts

    Drug: CLN-978

  • Experimental
    Part B Further Dose Evaluation

    Further evaluation of CLN-978 treatment of patients with Sjogren's Disease

    Drug: CLN-978

Interventions

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Incidence and severity of adverse events (AEs), serious AEs (SAEs), AEs of special interest (AESIs).

    Time frame: 48 weeks

Secondary outcomes

  1. To evaluate the PK of CLN-978

    Serum concentrations of CLN-978

    Time frame: 48 weeks

  2. Detection of anti-drug antibodies

    Detection of anti-drug antibodies

    Time frame: 48 weeks

  3. Change from baseline in B lymphocyte cell numbers in peripheral blood

    B lymphocyte cell numbers and change from baseline in peripheral blood

    Time frame: 48 weeks

07

Study locations

14 of 14 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 27, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Mar 15, 2028
CompletionEst.
Mar 15, 2029
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07041099
Lead sponsor
Cullinan Therapeutics Inc.
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Oct 1, 2025
Primary completion
Mar 15, 2028 (estimated)
Completion
Mar 15, 2029 (estimated)
Last update
Aug 11, 2026

Study contacts

Amy Gubits, MPH
Contact
ClinOps@cullinantx.com
+1 617 410 4650

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978

Start the discussion